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The presence and severity of ischemic left ventricular (LV)
systolic dysfunction is an important predictor of prognosis.
There are ample data demonstrating that for patients with
coronary artery disease and ischemic LV dysfunction, revas-
cularization is associated with a better prognosis compared
with medical therapy alone. In addition, varying degrees of
recovery of LV dysfunction can be observed after revascu-
larization. To predict which patients will benefit most from
surgical revascularization (and possibly which patients may
not benefit at all), attempts have been made to prospectively
assess the extent of myocardium that is dysfunctional but
viable. However, the published literature on testing for
myocardial viability is complicated, with conclusions that
are sometimes contradictory. To a large degree, this is due
to the disparate clinical scenarios in which myocardial
viability is evaluated, the different noninvasive techniques
used for its assessment, the vagaries of revascularization, and
the variety of outcomes measured.
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What is viable myocardium? The word “viable” implies
that something is living or cable of germination. However,
the term has been employed with varying meanings in the
context of ischemic heart disease. Myocardium that is
normally perfused and has normal contractile function is
obviously alive. Myocardial viability is typically questioned
in the setting of ischemic dysfunction, which occurs in two
settings: “stunning” is transient myocardial dysfunction that
complicates an acute cardiac event, whereas “hibernation” is
mechanical dysfunction that occurs because of ongoing
severe, chronic ischemia (1). Although it is probably easier
to detect than hibernating myocardium, stunned myocar-
dium recovers with the passage of time, and its identifica-
tion is therefore of relatively less importance. In contrast,
hibernating myocardium will not recover function without
relief of ischemia, typically with revascularization. Its detec-
tion relies on the demonstration of intact metabolism on
positron emission tomography, preserved cell membrane
integrity as a measure of cellular perfusion using nuclear
scintigraphy (and perhaps someday with myocardial con-
trast echocardiography), or contractile reserve using inotro-
pic stimulation and echocardiographic or magnetic reso-
nance imaging.
Because hibernating myocardium is subtended by a crit-
ically stenosed coronary artery, tracer uptake may be abnor-
mal, and demonstration of contractile reserve may be
limited by a competing ischemic response. Demonstration
of viability is further confounded by the heterogeneous
nature of dysfunctional myocardium, often involving
partial-thickness infarction in the same location (2).
Several “gold standards” have been used against which
testing for viable myocardium is judged. Recovery of re-
gional or global mechanical function after revascularization
serves as an attractive end point. However, recovery of
function is affected by other variables, including the extent
of partial-thickness infarction, the adequacy of revascular-
ization, intervening ischemic events between revasculariza-
tion and follow-up imaging, and concomitant medical
therapy. For these reasons, “viable” myocardium should
never have been taken as synonymous with “capable of
recovering mechanical function.” The strongest observations
to support this view relate to the prognostic implications of
revascularization independent of mechanical recovery.
Prognostic importance of viability. The existence of via-
ble myocardium among patients with ischemic LV dysfunc-
tion is a blade that cuts both ways. Among patients who
undergo revascularization, the presence of viable myocar-
dium portends the potential for symptomatic improvement
(3–5), recovery of mechanical function (5), and superior
prognosis (5,6). However, among patients who do not
undergo revascularization, viable myocardium is a marker
for poor prognosis (7,8). It appears that viable myocardium
is a boon if the patient undergoes revascularization and a
bane if the patient does not.
In an earlier editorial in the Journal (9) that accompanied
another study addressing myocardial viability testing and
prognosis, the question was raised whether it could be
justified to simply consider revascularization in all patients
with coronary artery disease and ischemic LV dysfunction.
However, the idea was doomed with perhaps the worst that
medical literature has available: noting that supporting data
are from nonrandomized studies in the surgical literature.
However, the issue remains pertinent. Knowledge that
patients with viable myocardium fare better after revascu-
larization than do those without viable myocardium is not
an argument to deny revascularization to patients without
viable myocardium. With the vagaries of myocardial viabil-
ity testing, what is the appropriate level of certainty that
viable myocardium is absent?
In this issue of the Journal, Sawada et al. (10) address the
incremental value of myocardial viability detected using
low-dose dobutamine stress echocardiography on the pre-
diction of prognosis five years after surgical revasculariza-
tion. They found that prognosis after coronary bypass
surgery is related to the presence and extent of viable
myocardium, and that the data contributed by low-dose
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dobutamine stress echocardiography are complementary to
clinical information and data derived from the baseline
echocardiogram. Several criteria were used to test the
presence of viability, including several measures of contrac-
tile reserve. Interestingly, measures of contractile reserve
were not predictive of prognosis after coronary bypass
grafting, whereas the simpler measure of wall motion score
index at low stress was.
How should viability be measured on echo? The failure
of contractile reserve to discriminate outcomes may come as
no surprise to those who read echocardiograms and attempt
to discern subtle changes in contractility in severely dysfunc-
tional myocardium. The interaction between severe under-
lying coronary stenosis, hibernation, intermittent stunning,
previous partial-thickness infarction, and a competing isch-
emic response makes the reliable identification of contractile
reserve a challenge at best. Although a “biphasic response”
on dobutamine stress echocardiograph is a specific predictor
of mechanical recovery after revascularization (11), it is
insensitive compared with simpler measures such as wall
thickness (12).
Wall motion score index is far from a precise measure of
LV function. The ventricle is nominally divided into 16
segments that bear some relationship to coronary anatomy,
and a semiquantitative system is used to classify contractil-
ity, dividing the sum of the scores of individual segments by
the number of segments scored. However, assigning numer-
ical values to qualitative descriptors is problematic. Is a
segment scored as “4” (dyskinetic) twice as bad as one scored
as “2” (hypokinetic)? Are the implications the same if all of
the left ventricle is hypokinetic as if half is normal and half
is akinetic, both with a wall motion score index of 2.0?
Ultimately, the shortfalls of the wall motion score index
may also be its advantage, and its use underscores the value
of the present study (10). Whereas other more esoteric
measures of myocardial viability may have appeal, calculat-
ing low-dose dobutamine wall motion score index is feasible
and reproducible. It incorporates data reflecting regional
and global contractile function as well as the presence of
ventricular aneurysm.
Limitations of the data. The study as presented assumes
that revascularization was complete if all diseased vessels
were bypassed. The quality of the diseased vessel and the
possibility of subsequent occlusion were not tested. As
Sawada et al. (10) note, the study was conducted over a time
of active evolution in medical therapy for ischemic LV
dysfunction, raising the question of whether the results
would be the same if the study were repeated using present
“state-of-the-art” medical therapy. There was the paradox-
ical finding that therapy with an angiotensin-converting
enzyme inhibitor was associated with worse outcome, pre-
sumably owing to its relationship to severity of congestive
heart failure rather than as an independent effect. The study
is based on surgical revascularization, and it is not known
whether the findings can be extrapolated to percutaneous
intervention.
Identifying candidates for coronary artery bypass surgery.
The study by Sawada et al. (10) addresses the survival
advantage associated with the presence and extent of viable
myocardium among patients with severe LV systolic dys-
function undergoing surgical coronary revascularization. It
does not address whether surgical revascularization has
advantages compared with medical therapy. Earlier studies
have demonstrated that patients with LV dysfunction and
viable myocardium fare better with revascularization than
with medical therapy alone (6–8,11). However, what of
patients without demonstrable myocardial viability?
A meta-analysis published in 2002 found that among
patients with ischemic LV dysfunction but without myo-
cardial viability, there was no significant difference in
survival between surgical intervention and medical therapy
(6). Earlier this year, Meluzı´n et al. (13) demonstrated a
trend that did not reach statistical significance toward better
survival with surgery (67% vs. 50% at 5 years) in the absence
of myocardial viability. From the surgical literature, Di Carli
et al. (14) demonstrated a trend toward better survival with
surgery in the absence of viable myocardium on positron
emission tomography if there were symptoms of angina
(100% vs. 60% at 4 years, p  0.085). Finally, Kleinkamp et
al. (15) reported that although the presence of viability was
associated with survival benefit with surgical revasculariza-
tion, the quality of the coronary arteries was a stronger
predictor of benefit. Although none of these studies proves
a survival advantage with surgery in patients without de-
monstrable viability, some reveal a trend favoring revascu-
larization and none show a detrimental effect. It is unknown
whether the absence of a statistically significant improve-
ment in survival with surgery is due to no actual survival
advantage; a smaller advantage than among patients with
viable myocardium, such that trends fail to reach statistical
significance; or heterogeneity of the population without
demonstrable myocardium, such that some patients benefit
and others do not.
Pascal’s Wager and coronary revascularization. The
seventeenth-century mathematician Blaise Pascal is perhaps
best known for Pascal’s triangle, a mathematical array in
which each entry is the sum of the two numbers directly
above it. A philosopher, Pascal is also known for Pascal’s
Wager: “If you believe in God and turn out to be incorrect,
you have lost nothing—but if you don’t believe in God and
turn out to be incorrect, you will go to hell. Therefore it is
foolish to be an atheist.” Religious implications notwith-
standing, the message is that decisions should weigh con-
sequences in addition to probabilities.
Prognosis is poor among patients with coronary artery
disease and severe LV dysfunction, and improved with
surgical revascularization. The presence of viable myocar-
dium is a strong predictor of improved survival with
revascularization, but a marker for worse prognosis without
revascularization. For patients with viable myocardium,
there appears to be no remaining uncertainty that revascu-
larization is indicated; future research will continue to define
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the respective roles of surgical and percutaneous techniques
even as both continue to evolve. However, the detection of
viability is not exact, and available tests are imperfect.
Because coronary artery bypass surgery does not appear to
adversely affect survival in the absence of viable myocar-
dium, why not exclude patients who are at especially high
risk for bypass surgery (16) and refer the rest for revascu-
larization?
Because it is appropriate to weigh consequences in
addition to probabilities, the risks of failing to intervene
should be considered, realizing that testing for viability is
imperfect. Among patients with severe LV systolic dysfunc-
tion and reasonable surgical targets who are not at excessive
risk for surgical revascularization, the consequences of
failing to intervene may outweigh the risks of intervention,
even if testing fails to detect viable myocardium. Specifi-
cally, in the absence of a contraindication, it may be very
reasonable to intervene regardless of the presence or absence
of viability.
Should we test for viability at all? If patients undergo
revascularization regardless of the results, there is little
rationale for preoperative testing. Some patients will still fall
into “gray” areas, with moderate or greater risk for surgery
and arterial targets that are less than ideal. Among such
patients, testing for myocardial viability provides useful data
that could help sway decisions toward or away from inter-
vention. However, among patients in whom risk is not
excessive, it may be the most prudent option to perform
revascularization without testing for viability. Although
some patients benefit from intervention more than others
do, the risks of not intervening mitigate against a more
conservative strategy.
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